Mildronate (Meldonium Dihydrate)

Meldonium inhibits the enzyme gamma‑butyrobetaine hydroxylase, which reduces the synthesis of carnitine. Lower carnitine levels limit fatty‑acid oxidation in heart muscle cells and promote glucose oxidation, a more oxygen‑efficient energy pathway that protects the heart during ischemic stress.

The dosage of Mildronate is determined by the prescribing physician based on the patient’s clinical condition, severity of disease, and response to therapy. No fixed regimen is provided here; the prescriber sets the appropriate dose and administration schedule.

The safety of meldonium in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and clinicians should weigh potential benefits against possible risks before prescribing to pregnant or nursing women.

To request Mildronate, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Mildronate differs from traditional anti‑ischemic drugs such as nitrates or beta‑blockers by targeting myocardial metabolism rather than vascular tone. It reduces reliance on fatty‑acid oxidation, which can improve cardiac efficiency without the vasodilatory side effects seen with some alternatives.

Mildronate injectable solution should be stored at 2‑8 °C. Keep the product refrigerated, protect it from light, and avoid freezing or shaking the container to maintain stability and potency.

Mildronate is administered intravenously by a qualified healthcare professional. The solution is injected directly into a vein, typically in a clinical setting, following the dosage and infusion rate prescribed by the treating physician.

Serious risks, though rare, include severe allergic reactions (anaphylaxis), significant hepatic enzyme elevation, cardiac arrhythmias, and profound hypotension. Patients should be monitored for these events, especially when receiving high‑dose or prolonged therapy.

Mildronate is contraindicated in individuals with known hypersensitivity to meldonium or any of its excipients. Caution is also advised for patients with severe renal or hepatic impairment, uncontrolled hypertension, or those taking medications that may interact strongly with its metabolic pathway.